Business
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targeting BCMA) have been presented as a poster at the 22nd International Myeloma Society ("IMS") Annual Meeting. The poster was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refrac
About this update from Carsgen Therapeutics Holdings Ltd.
[{"type":"text","content":"SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targeting BCMA) have been presented as a poster at the 22nd International Myeloma Society ("IMS") Annual Meeting. The poster was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" (Abstract number: PA-029).","length":614,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/科济药业)","displaySize":"","headline":null,"caption":"(PRNewsfoto/科济药业)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/5526ae7fcec6d3697a745ab2d0333d4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pxBnvmJ9CDgFxmtruRHsdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5526ae7fcec6d3697a745ab2d0333d4b","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/1722549/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In this study, a total of 14 patients with relapsed or refractory multiple myeloma (R/R MM) received a single infusion of zevor-cel. As of February 22, 2025, the median follow-up duration was 53.3 months (range:14.8, 63.5).","length":223,"tagName":"p"},{"type":"text","content":"Regarding safety: There were no reports of ≥Grade 3 cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy or other delayed AEs on the study.","length":234,"tagName":"p"},{"type":"text","content":"Regarding efficacy: The overall response rate was 100% (95% CI: 76.8, 100.0) with 11 (78.6%) patients achieving complete response (CR) or stringent complete response (sCR). All patients who achieved CR or better were minimal residual disease (MRD) negative at 10−5 threshold. One patient remained in sCR at 59.3 months in the study. The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively. The ...